Cirrhosis News and Research

Latest Cirrhosis News and Research

Incarcerated patients with chronic HCV likely to achieve sustained viral response

Incarcerated patients with chronic hepatitis C virus (HCV) infection are just as likely to respond to treatment for the disease as patients in the community, according to findings published in the October issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases.

28 Sep 2012

Dietary habits associated with NAFLD in obese children

Research has identified a number of variables associated with nonalcoholic fatty liver disease in obese children.

27 Sep 2012

Postsurgery mortality rates vary across Europe

Europe-wide data suggest that mortality rates after noncardiac surgery are higher than expected, and vary substantially by country, reports an international research team in The Lancet.

27 Sep 2012

PPI use linked with risk for infection in decompensated cirrhosis

Proton-pump inhibitors are associated with an increased risk for serious infections in patients with decompensated cirrhosis, research shows.

24 Sep 2012

UMDNJ, Proteonomix to conduct UMK-121 Phase 1 trial in end-stage liver disease

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced it has entered into an agreement with Piscataway, N.J.-based University of Medicine and Dentistry of New Jersey (UMDNJ) to conducted a Phase 1 clinical trial with its proprietary, patent-pending mobilization technology UMK-121 in patients with end-stage liver disease (ESLD).

15 Sep 2012

Researchers identify three genetic regions associated with primary biliary cirrhosis

Researchers have newly identified three genetic regions associated with primary biliary cirrhosis (PBC), the most common autoimmune liver disease, increasing the number of known regions associated with the disorder to 25.

10 Sep 2012

GSK, University of Cambridge aim to discover and develop new medicines for liver disease

A new collaboration based at the University of Cambridge will aim to discover and develop new medicines to treat liver disease.

10 Sep 2012

Children and young patients with chronic HBV infection do have a protective immune response

Scientists from A*STAR's Singapore Institute for Clinical Sciences (SICS), together with clinical collaborators from London , discovered for the first time that children and young patients with chronic Hepatitis B Virus infection (HBV carriers) do have a protective immune response, contrary to current belief, and hence can be more suitable treatment candidates than previously considered.

7 Sep 2012

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

The drug telaprevir has been available for treatment of chronic hepatitis C infection of genotype 1 since autumn 2011. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether telaprevir offers an added benefit compared with the present standard therapy.

6 Sep 2012

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

Soligenix, Inc., a development stage biopharmaceutical company, announced today that the National Cancer Institute has awarded Soligenix a Small Business Innovation Research grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestation of chronic Graft-versus-Host disease.

5 Sep 2012

Southampton Traffic Light test could easily diagnose liver fibrosis and cirrhosis

A new 'traffic light' test devised by Dr Nick Sheron and colleagues at University of Southampton and Southampton General Hospital could be used in primary care to diagnose liver fibrosis and cirrhosis in high risk populations more easily than at present.

30 Aug 2012

Corporate power presents a major threat to public health

Professor Gerard Hastings from the Institute for Social Marketing at the University of Stirling argues that marketing by multinational corporations "threatens our mental wellbeing, exacerbates inequalities, and encourages unsustainable consumption."

22 Aug 2012

CDC: Baby boomers should be tested for Hep C

Americans born between 1945 and 1965 are at particularly high risk for Hepatitis C and should be tested, according to new recommendations from the Centers for Disease Control and Prevention.

18 Aug 2012

Researchers identify molecular and protein signatures that predict HCV virus-induced liver injury

Researchers have discovered molecular and protein signatures that predict rapid onset of liver damage in hepatitis C patients following a liver transplant. The markers appeared soon after transplant and well before clinical evidence of liver damage.

17 Aug 2012

FibroGen receives FDA Orphan Drug Designation for FG-3019 to treat IPF

FibroGen, Inc., today announced that FG-3019, the Company's human monoclonal antibody against connective tissue growth factor (CTGF), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).

31 Jul 2012

Researchers identify new genetic target for diuretic therapy

Researchers at the University of Cincinnati (UC) have identified a new genetic target for diuretic therapy in patients with fluid overload-like those with congestive heart failure, liver cirrhosis or kidney failure.

31 Jul 2012

Enoxaparin prevents PVT in advanced cirrhosis

Enoxaparin significantly reduces portal vein thrombosis and increases overall survival in patients with advanced cirrhosis, the results of an Italian study show.

30 Jul 2012

EASL calls on the UN to take action to fight against viral hepatitis infection

Marking World Hepatitis Day, the European Association for the Study of the Liver (EASL) calls on the different organizations which make up the United Nations systems to take action to fight against Viral Hepatitis (Hepatitis B and C), a potentially fatal infection of the liver which affects 500 million people.

30 Jul 2012

Viral evolution and host protein levels predict rapid disease progression in hepatitis C patients

Scientists at the National Institutes of Health have identified several factors in people infected with the hepatitis C virus that may predict whether the unusually rapid progression of disease from initial infection to severe liver conditions, such as cirrhosis, will occur. Knowing whether a patient's condition is likely to deteriorate quickly could help physicians decide on the best course of treatment.

27 Jul 2012

Vitamin B12 supplements and hepatitis C treatment: an interview with Gerardo Nardone and Alba Rocco

Since its discovery in 1989, hepatitis C virus (HCV) has been recognized as a major cause of chronic liver disease worldwide. The most recent WHO estimate of the prevalence of HCV infection is 2%, representing . about 150 million people. Every year, 3–4 million new people are infected with the hepatitis C virus, of those, approximately 60–80% develop chronic hepatitis, and 30% of them progress to cirrhosis and to end-stage liver disease.

26 Jul 2012

Cirrhosis News and Research

Latest Cirrhosis News and Research

Incarcerated patients with chronic HCV likely to achieve sustained viral response

Dietary habits associated with NAFLD in obese children

Postsurgery mortality rates vary across Europe

PPI use linked with risk for infection in decompensated cirrhosis

UMDNJ, Proteonomix to conduct UMK-121 Phase 1 trial in end-stage liver disease

Researchers identify three genetic regions associated with primary biliary cirrhosis

GSK, University of Cambridge aim to discover and develop new medicines for liver disease

Children and young patients with chronic HBV infection do have a protective immune response

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

Southampton Traffic Light test could easily diagnose liver fibrosis and cirrhosis

Corporate power presents a major threat to public health

CDC: Baby boomers should be tested for Hep C

Researchers identify molecular and protein signatures that predict HCV virus-induced liver injury

FibroGen receives FDA Orphan Drug Designation for FG-3019 to treat IPF

Researchers identify new genetic target for diuretic therapy

Enoxaparin prevents PVT in advanced cirrhosis

EASL calls on the UN to take action to fight against viral hepatitis infection

Viral evolution and host protein levels predict rapid disease progression in hepatitis C patients

Vitamin B12 supplements and hepatitis C treatment: an interview with Gerardo Nardone and Alba Rocco

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cirrhosis News and Research

Latest Cirrhosis News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in